Ontada to present 14 data presentations at ISPOR 2025 including a podium presentation on distress thermometer screening in US oncology setting ...

today announced that the company will present three posters related to both of its pipeline programs at the American Thoracic Society (ATS) 2025 International Conference (ATS 2025). ATS 2025 is ...

today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28ᵗʰ Annual Meeting being held May 13 - 17 in New Orleans, LA as ...

TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

The abstracts are scheduled to be posted to the AACR Online Program Planner at 4:30 PM ET on Tuesday, March 25. About AACR The American Association for Cancer Research (AACR) is the first and ...

today announced the presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago. The presentation describes the company’s ...

CONCORD, Mass.–(BUSINESS WIRE)–ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that an abstract will be ...

IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible ...

Two abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technology Differentiated preclinical activity for CAB anti-Nectin4-antibody ...

will be highlighted in an oral presentation. In addition, a trial-in-progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic ...

Adagene Inc. announced a poster presentation for the ASCO 2025 conference in Chicago, highlighting the safety and efficacy of its product, ADG126, an anti-CTLA-4 masking antibody, in combination ...

This “trial-in-progress” presentation will focus on the design of the ongoing expansion portion of Mersana’s Phase 1 clinical trial of Emi-Le that is actively enrolling patients with triple ...